Under the terms of the agreement, the Par Sterile facility in Rochester initiated production of the definitive pharmaceutical product NVX-CoV2373, and the initial batches will be used in Novavax’s fundamental Phase 3 clinical trial in the United States. NVX-CoV2373 vaccine for advertising distribution in the United States. The financial or other terms of the agreement were not disclosed.
